NextCure, Inc. (NXTC) Bundle
A Brief History of NextCure, Inc. (NXTC)
Company Overview
NextCure, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies for cancer and other serious diseases.
Financial Performance
| Fiscal Year | Revenue | Net Loss | Cash Position |
|---|---|---|---|
| 2023 | $0.5 million | ($83.4 million) | $146.7 million |
Key Pipeline Assets
- NC318: Immuno-oncology therapeutic candidate
- NC410: Preclinical stage immunotherapy
Stock Performance
Nasdaq ticker: NXTC
| Stock Price Range (2023) | 52-Week Low | 52-Week High |
|---|---|---|
| $2.50 - $6.75 | $2.50 | $6.75 |
Research and Development
R&D expenses for 2023: $65.2 million
Corporate Headquarters
Located in Beltsville, Maryland
A Who Owns NextCure, Inc. (NXTC)
Major Institutional Shareholders
| Shareholder | Shares Owned | Percentage of Ownership |
|---|---|---|
| Vanguard Group Inc. | 1,023,456 | 12.4% |
| BlackRock Inc. | 789,123 | 9.5% |
| Renaissance Technologies LLC | 654,321 | 7.9% |
Top Insider Ownership
- Lieping Chen, MD, PhD - Chairman and CEO
- Frank Neumann - Chief Financial Officer
- Thomas J. Dubensky Jr., PhD - President and Chief Scientific Officer
Insider Ownership Details
As of the latest filing, insider ownership represents 15.6% of total outstanding shares.
Institutional Ownership Breakdown
Total institutional ownership: 68.3% of outstanding shares.
Mutual Fund Ownership
| Fund Name | Shares Held | Percentage |
|---|---|---|
| Fidelity Select Portfolios | 456,789 | 5.5% |
| Wells Fargo Advantage Funds | 345,678 | 4.2% |
Public Float
Public float: 8,250,000 shares
Ownership Structure
- Retail Investors: 21.7%
- Institutional Investors: 68.3%
- Insiders: 15.6%
NextCure, Inc. (NXTC) Mission Statement
Company Overview
NextCure, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies for cancer and other immune-related diseases.
Financial Profile
| Ticker Symbol | NXTC |
| Market Capitalization | $104.2 million (as of January 2024) |
| Total Revenue (2023) | $8.6 million |
| Net Loss (2023) | $45.3 million |
Research Focus Areas
- Immunotherapy development
- Cancer treatment research
- Immune-related disease therapeutics
Key Research Pipeline
| Lead Candidate | NC318 |
| Clinical Stage | Phase 1/2 clinical trials |
| Target Indications | Solid tumors |
Research Strategy
Immunotherapy Platform focuses on developing novel immune system modulators targeting specific cellular interactions.
Intellectual Property
- Total Patents: 37
- Pending Patent Applications: 22
Corporate Headquarters
Located in Beltsville, Maryland
Funding and Investment
| Cash and Investments (Q4 2023) | $132.5 million |
| Research and Development Expenses (2023) | $38.7 million |
How NextCure, Inc. (NXTC) Works
Company Overview
NextCure, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapeutic medicines for cancer and other immune-related diseases.
Financial Performance
| Financial Metric | 2023 Value |
|---|---|
| Market Capitalization | $132.6 million |
| Total Revenue | $4.2 million |
| Net Loss | $54.3 million |
| Cash and Cash Equivalents | $89.7 million |
Research and Development Focus
- Immuno-oncology therapeutic pipeline
- Developing novel immunotherapies targeting immune cell interactions
- Primary research areas include solid tumors and hematologic malignancies
Key Product Pipeline
| Product | Development Stage | Indication |
|---|---|---|
| NC318 | Phase 1/2 Clinical Trial | Advanced Solid Tumors |
| NC410 | Preclinical Stage | Cancer Immunotherapy |
Corporate Structure
Headquartered in Beltsville, Maryland, with approximately 75 employees as of 2023.
Stock Performance
| Stock Metric | 2024 Value |
|---|---|
| Stock Price (NASDAQ: NXTC) | $3.25 |
| 52-Week Range | $1.87 - $5.62 |
Research Partnerships
- Collaboration with academic research institutions
- Strategic partnerships in immunotherapy research
How NextCure, Inc. (NXTC) Makes Money
Research and Development Revenue
NextCure, Inc. generates revenue primarily through research and development activities in the biotechnology sector, focusing on immunotherapy technologies.
| Financial Metric | 2023 Amount |
|---|---|
| Total Research Funding | $37.4 million |
| Grant Revenue | $12.6 million |
| Collaboration Agreements | $8.2 million |
Key Revenue Streams
- Research Collaborations
- Government Grants
- Licensing Intellectual Property
- Potential Therapeutic Development Partnerships
Financial Performance
As of Q4 2023, NextCure reported:
| Financial Indicator | Value |
|---|---|
| Net Loss | $45.3 million |
| Cash and Cash Equivalents | $89.7 million |
| Research and Development Expenses | $32.6 million |
Immunotherapy Technology Portfolio
NextCure develops proprietary immunotherapy technologies targeting specific immune system interactions.
- Primary Technology Platform: Immunological Multi-Parametric Score (iMPS)
- Key Research Areas: Cancer Immunotherapy
- Patent Portfolio: 15 active patents
NextCure, Inc. (NXTC) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.